STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
Adam Feuerstein·
·1 min read
·
0 reactions
·
0 comments
·
9 views
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Original article
STAT · Adam Feuerstein
Anonymous · no account needed
Discussion
0 commentsMore from STAT
STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
STAT·10
Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
STAT·7
Opinion: The medical-billing AI arms race between providers and insurance
STAT·8
Opinion: The Amish way of health care
STAT·7
Opinion: How the military may be fueling eating disorders in men
STAT·9
STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
STAT·10